Vasopressin, steroids, and epinephrine in out-of-hospital cardiac arrest - a protocol for a randomized controlled trial (OHCA REVIVES trial).
Ying-Chih Ko, Yu-You Lin, Wen-Shuo Yang...
https://pubmed.ncbi.nlm.nih.gov/41399685/Actively Recruiting
Led by National Taiwan University Hospital · Updated on 2025-11-19
1344
Participants Needed
1
Research Sites
21 weeks
Total Duration
Researchers are evaluating the effects of different drug treatments on adult patients who suffer sudden non-traumatic out-of-hospital cardiac arrest OHCA and are resuscitated by advanced paramedics in Taipei City and New Taipei City. The study compares a combination therapy of epinephrine, vasopressin, and methylprednisolone against standard epinephrine treatment alone to see which improves sustained recovery of spontaneous circulation ROSC and long-term survival. This randomized clinical trial, called the OHCA-REVIVES trial, aims to find the best prehospital medication strategy to improve survival outcomes after OHCA. The trial includes two groups the intervention group receives combined drug treatment with epinephrine every 3-5 minutes, vasopressin every 3-5 minutes up to 80 units total, and one dose of methylprednisolone after the first epinephrine dose. The control group receives standard treatment with epinephrine every 3-5 minutes only. These medications are administered before hospital arrival by paramedics trained in the trial procedures. The study expects to enroll approximately 1,344 patients over about 30 months. Participants are assessed for the primary outcome of sustained ROSC lasting about 2 hours, along with secondary outcomes including prehospital ROSC, survival to hospital discharge, and survival with good neurological status up to 30 days. Data collection occurs during prehospital care and hospital stay. The study follows patients to evaluate the effects of the drug treatments on recovery and survival after cardiac arrest. Enrollment started in mid-2024 and is expected to continue until the end of 2026.
CONDITIONS
The Effect of Prehospital Combination of Epinephrine, Vasopressin, and Steroid in OHCA
W
WEN CHU CHIANG, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Taiwan University Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Screening and enrollment occur during emergency response before hospital arrival
Duration - Administered during prehospital emergency care until hospital arrival
Participants receive either standard epinephrine therapy or a combination of epinephrine, vasopressin, and methylprednisolone administered by paramedics in a prehospital emergency setting for out-of-hospital cardiac arrest.
Single prehospital treatment episode during emergency response
Duration - Up to 30 days after treatment
Participants are monitored for survival outcomes and neurological status after hospital admission.
Assessments at approximately 1 hour, 2 hours, and 30 days post-treatment
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Ying-Chih Ko, Yu-You Lin, Wen-Shuo Yang...
https://pubmed.ncbi.nlm.nih.gov/41399685/National Taiwan University Hospital
Lead Sponsor